Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Blinded Phase II Study Investigating the Treatment of Acute Large Hemispheric Infarction by Transcranial Bone Marrow Injection of RK-4 Injection

NCT07203521 is registered in ClinicalTrials.gov with Fuzhou Neurodawn Rongkang Pharmaceutical Co., Ltd as lead sponsor.

NCT NCT07203521
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07203521 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Blinded Phase II Study Investigating the Treatment of Acute Large Hemispheric Infarction by Transcranial Bone Marrow Injection of RK-4 Injection
Lead sponsor
Fuzhou Neurodawn Rongkang Pharmaceutical Co., Ltd
Phase
Phase 2
Overall status
Not yet recruiting
Start date
November 1, 2025
Completion date
October 7, 2026
Enrollment
194 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

acute ischemic stroke, acute large hemispheric infarction stroke, rk-4, transcranial bone marrow injection